Nuclear Receptors Conference 2018

Nuclear Receptors Conference is organized by Fusion Conferences ltd and will be held during Feb 27 - Mar 02, 2018 at Fiesta Americana Condesa Cancun All Inclusive, Cancun, Quintana Roo, Mexico.

The target audience for this medical event is Scientists and Clinician Scientists at a range of levels from postdoctoral and up: Principal Investigators, Junior Team Leaders, Research Fellows. Ambitious postgraduate students in the field will also be encouraged to attend.

Conference Description :
Relevant specialties are wide-ranging, reflecting the importance of nuclear receptors in many aspects of health and disease. These include Endocrinology, Oncology, Paediatrics, Urology, Gynaecology, Obstetric Medicine, Neuroscience, Cardiology.

Nuclear Receptors are, physiologically and pharmacologically, a critical superfamily of transcription factors. They drive key processes at every stage of development and reproduction to aging and cancer. They are critical determinants of everyday health via their roles in metabolism and circadian rhythms. Nuclear receptors allow external factors to influence cellular pathways and the fact that many binds and are activated by small molecules means they represent highly druggable targets; currently, 13% of FDA-approved drugs target nuclear receptors.

This meeting will address the new roles and novel crosstalk mechanisms that are emerging for many of the 48 human nuclear receptors, in health and disease. For example, it has long been known that the estrogen receptor drives progression of breast cancer, and patients with estrogen receptor-positive disease are treated using antiestrogens or aromatase inhibitors to inhibit estrogen signaling. Now, however, it is apparent that the androgen receptor can in some cases drive breast cancer progression and is a therapeutic target, resulting in clinical trials for androgen receptor-targeting therapies in advanced breast cancer. The androgen receptor, itself long the main therapeutic target in prostate cancer, is emerging as a key player in metabolic disease, while conversely other nuclear receptors including the glucocorticoid receptor and several orphan nuclear receptors are implicated in prostate cancer progression. Meanwhile, given the impact of many nuclear receptors on the central nervous system, it is unsurprising that they are being explored in the context of neurological disorders and depression. Thus there is wide scope for re-purposing of licensed drugs and development of new NR-targeting therapies for a host of conditions and diseases.

Key Sessions :
• Further emerging roles for nuclear receptors in cancer
• Structural insights into nuclear receptor function and crosstalk
• Nuclear receptors’ role in epigenetic regulation and non coding RNA
• Nuclear receptors and DNA damage
• Nuclear receptors and cell cycle
• Nuclear receptors in metabolism/metabolic disease
• Nuclear receptors in the CNS